Granisetron (Group G) — Competitive Intelligence Brief

Granisetron (Group G) (Granisetron (Group G)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology, Gastroenterology.

marketed 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology Small molecule

Target snapshot

Granisetron (Group G) (Granisetron (Group G)) — University of Malaya. Granisetron is a selective serotonin 5-HT3 receptor antagonist that blocks nausea and vomiting signals in the chemoreceptor trigger zone and gastrointestinal tract.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Granisetron (Group G) TARGET	Granisetron (Group G)	University of Malaya	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Ondansetron Intraperitoneal Lavage	Ondansetron Intraperitoneal Lavage	Instituto Mexicano del Seguro Social	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Sodium Bicarbonate Powder and ondansetron	Sodium Bicarbonate Powder and ondansetron	Aya Sabry Mohamed Mohamed	marketed	Antacid and antiemetic combination	5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
Ondansetron orodispersible film once	Ondansetron orodispersible film once	Chongqing University Cancer Hospital	marketed	5-HT3 receptor antagonist	5-HT3 receptor
Dexamethasone and ondansetron	Dexamethasone and ondansetron	Yeditepe University Hospital	marketed	Corticosteroid + 5-HT3 receptor antagonist combination	Glucocorticoid receptor (dexamethasone); 5-HT3 receptor (ondansetron)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

1. Helsinn Healthcare SA · 4 drugs in this class
2. LG Life Sciences · 3 drugs in this class
3. University of Malaya · 2 drugs in this class
4. GlaxoSmithKline · 1 drug in this class
5. Hamad Medical Corporation · 1 drug in this class
6. Eye & ENT Hospital of Fudan University · 1 drug in this class
7. Instituto Mexicano del Seguro Social · 1 drug in this class
8. Chongqing University Cancer Hospital · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class
10. MonoSol Rx · 1 drug in this class